Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.
10.1007/s11684-023-1041-7
- Author:
Lu LIU
1
;
Chenxia ZHOU
1
;
Huimin JIANG
2
;
Huimin WEI
3
;
Yifan ZHOU
2
;
Chen ZHOU
4
;
Xunming JI
5
Author Information
1. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100032, China.
2. Beijing Institute of Brain Disorders, Capital Medical University, Beijing, 100069, China.
3. Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100191, China.
4. Beijing Institute of Brain Disorders, Capital Medical University, Beijing, 100069, China. chenzhou2013abc@163.com.
5. Neurology and Intracranial Hypertension and Cerebral Venous Disease Center, National Health Commission of China, Xuanwu Hospital, Capital Medical University, Beijing, 100032, China. jixm@ccmu.edu.cn.
- Publication Type:Review
- Keywords:
SARS-CoV-2;
cerebral venous thrombosis;
hemorrhagic stroke;
ischemic stroke;
stroke;
vaccination
- MeSH:
Humans;
COVID-19/complications*;
SARS-CoV-2;
Stroke/therapy*
- From:
Frontiers of Medicine
2023;17(6):1047-1067
- CountryChina
- Language:English
-
Abstract:
The Coronavirus disease 2019 (COVID-19) epidemic has triggered a huge impact on healthcare, socioeconomics, and other aspects of the world over the past three years. An increasing number of studies have identified a complex relationship between COVID-19 and stroke, although active measures are being implemented to prevent disease transmission. Severe COVID-19 may be associated with an increased risk of stroke and increase the rates of disability and mortality, posing a serious challenge to acute stroke diagnosis, treatment, and care. This review aims to provide an update on the influence of COVID-19 itself or vaccines on stroke, including arterial stroke (ischemic stroke and hemorrhagic stroke) and venous stroke (cerebral venous thrombosis). Additionally, the neurovascular mechanisms involved in SARS-CoV-2 infection and the clinical characteristics of stroke in the COVID-19 setting are presented. Evidence on vaccinations, potential therapeutic approaches, and effective strategies for stroke management has been highlighted.
